ArticleTranslational oncology2026
THOC3 interacts with epithelial-to-mesenchymal transition to promote non-small cell lung cancer carcinoma progression through STAT3 signaling pathway.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).International journal of oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Located on chromosome 5, the THOC3 gene encodes a protein of 351 amino acids, though its precise biological role in various malignancies, including lung cancer (LC), remains to be fully clarified. Elevated expression of THOC3 was observed in LC (IHC) analyses. Increased THOC3 levels were associated with advanced tumor stages and poorer prognosis in patients. Functional studies using both loss-of-function and gain-of-function approaches suggested that THOC3 may influence cellular proliferation, tumorigenic potential, and apoptosis in vitro. Mechanistically, its effects appear to involve activation of the STAT3 pathway. Additionally, Garcinone d-induced STAT3 activation mitigated certain malignant characteristics of LC cells, though silencing THOC3 reversed this effect. These results indicate that THOC3 may serve as a potential prognostic marker and could warrant further investigation as a therapeutic target in LC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.